Rheumatoid Arthritis Industry, March 2015 Market Reports from Top Publishers

You might be interested in: Diagnostics, Biosimilar, Drug, Pharmaceutical, Orthopedic Prosthesis, Antibody, Biosimilars, Cell Therapy, Clinical Trial, Monoclonal Antibody, Pain Management Therapeutics, Sports Medicine.


 
1-10 of 58 reports for Rheumatoid Arthritis

Purchase Reports From Reputable Market Research Publishers

Sjogren%s Syndrome - Pipeline Review, H2 2014

Sjogren%s Syndrome - Pipeline Review, H2 2014

  • $ 2 000
  • Industry report
  • December 2014
  • by Global Markets Direct

Sjogren's Syndrome - Pipeline Review, H2 2014 Summary Global Markets Direct’s, ‘Sjogren's Syndrome - Pipeline Review, H2 2014’, provides an overview of the Sjogren's Syndrome’s therapeutic pipeline. ...

Systemic Juvenile Rheumatoid Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Systemic Juvenile Rheumatoid Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight’s, “Systemic Juvenile Rheumatoid Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs ...

Juvenile Rheumatoid Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Juvenile Rheumatoid Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight’s, “Juvenile Rheumatoid Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed ...

Rheumatoid Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Rheumatoid Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight’s, “Rheumatoid Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs ...

PharmaPoint: Rheumatoid Arthritis - US Drug Forecast and Market Analysis to 2023

PharmaPoint: Rheumatoid Arthritis - US Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Rheumatoid Arthritis - US Drug Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. ...

PharmaPoint: Rheumatoid Arthritis - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Rheumatoid Arthritis - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Rheumatoid Arthritis - 5EU Drug Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. ...

PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. ...

PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis to 2023

PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the ...

PharmaPoint: Rheumatoid Arthritis - China Drug Forecast and Market Analysis to 2023

PharmaPoint: Rheumatoid Arthritis - China Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Rheumatoid Arthritis - China Drug Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. ...

PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis to 2023

PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. ...

About 3 200 reports for Rheumatoid Arthritis

Download Unlimited Documents from Trusted Public Sources

Pathology Description in the UK

  • June 2013
    28 pages
  • Rheumatoid Arth...  

    Rheumatology  

  • United Kingdom  

View report >

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.